Does the media prefer TXG or TWST?

In the previous week, Twist Bioscience had 9 more articles in the media than 10x Genomics. MarketBeat recorded 19 mentions for Twist Bioscience and 10 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 0.35 beat Twist Bioscience's score of 0.10 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 1 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Twist Bioscience 7 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, IQV or TXG?

IQVIA has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IQVIA $16.31B 2.69 $1.36B $8.06 33.07 10x Genomics $642.82M 19.81 -$43.54M -$0.59 N/A

Is IQV or TXG more profitable?

IQVIA has a net margin of 8.10% compared to 10x Genomics' net margin of -12.18%. IQVIA's return on equity of 30.25% beat 10x Genomics' return on equity. Company Net Margins Return on Equity Return on Assets IQVIA 8.10% 30.25% 6.54% 10x Genomics -12.18% -9.33% -7.30%

Does the media favor IQV or TXG?

In the previous week, IQVIA had 3 more articles in the media than 10x Genomics. MarketBeat recorded 13 mentions for IQVIA and 10 mentions for 10x Genomics. IQVIA's average media sentiment score of 0.51 beat 10x Genomics' score of 0.35 indicating that IQVIA is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IQVIA 3 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 10x Genomics 1 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, TXG or WAT?

Waters has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 10x Genomics $642.82M 19.81 -$43.54M -$0.59 N/A Waters $3.17B 13.67 $642.63M $4.01 109.84

Is TXG or WAT more profitable?

Waters has a net margin of 3.58% compared to 10x Genomics' net margin of -12.18%. Waters' return on equity of 11.27% beat 10x Genomics' return on equity. Company Net Margins Return on Equity Return on Assets 10x Genomics -12.18% -9.33% -7.30% Waters 3.58% 11.27% 6.73%

Does the media prefer TXG or WAT?

In the previous week, 10x Genomics and 10x Genomics both had 10 articles in the media. 10x Genomics' average media sentiment score of 0.35 beat Waters' score of 0.22 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 1 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Waters 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, TXG or ILMN?

Illumina has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 10x Genomics $642.82M 19.81 -$43.54M -$0.59 N/A Illumina $4.34B 10.21 $850M $5.36 54.79

Is TXG or ILMN more profitable?

Illumina has a net margin of 18.36% compared to 10x Genomics' net margin of -12.18%. Illumina's return on equity of 29.84% beat 10x Genomics' return on equity. Company Net Margins Return on Equity Return on Assets 10x Genomics -12.18% -9.33% -7.30% Illumina 18.36% 29.84% 12.17%

Does the media prefer TXG or ILMN?

In the previous week, Illumina had 10 more articles in the media than 10x Genomics. MarketBeat recorded 20 mentions for Illumina and 10 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 0.35 beat Illumina's score of 0.29 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 1 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Illumina 7 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

10x Genomics (TXG) Competitors

$80.66 -17.08 (-17.47%)

Closing price 04:00 PM Eastern

Extended Trading

$80.96 +0.30 (+0.37%)

As of 07:58 PM Eastern

Compare

TXG vs. PACB, TWST, IQV, WAT, and ILMN

Should you buy 10x Genomics stock or one of its competitors? 10x Genomics's main competitors and comparable companies include Pacific Biosciences of California (PACB), Twist Bioscience (TWST), IQVIA (IQV), Waters (WAT), and Illumina (ILMN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does 10x Genomics compare to Pacific Biosciences of California?

10x Genomics (NASDAQ:TXG) and Pacific Biosciences of California (NASDAQ:PACB) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

10x Genomics currently has a consensus target price of $53.93, indicating a potential downside of 44.82%. Pacific Biosciences of California has a consensus target price of $1.71, indicating a potential downside of 40.33%. Given Pacific Biosciences of California's higher probable upside, analysts plainly believe Pacific Biosciences of California is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.28
Pacific Biosciences of California	2 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.83

84.7% of 10x Genomics shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by company insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

10x Genomics has a net margin of -12.18% compared to Pacific Biosciences of California's net margin of -82.49%. 10x Genomics' return on equity of -9.33% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-12.18%	-9.33%	-7.30%
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%

In the previous week, 10x Genomics had 1 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 10 mentions for 10x Genomics and 9 mentions for Pacific Biosciences of California. Pacific Biosciences of California's average media sentiment score of 0.45 beat 10x Genomics' score of 0.35 indicating that Pacific Biosciences of California is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	1 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pacific Biosciences of California	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

10x Genomics has a beta of 1.99, suggesting that its share price is 99% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market.

10x Genomics has higher revenue and earnings than Pacific Biosciences of California. 10x Genomics is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	19.81	-$43.54M	-$0.59	N/A
Pacific Biosciences of California	$160.01M	5.58	-$546.38M	-$0.43	N/A

Summary

10x Genomics beats Pacific Biosciences of California on 11 of the 16 factors compared between the two stocks.

How does 10x Genomics compare to Twist Bioscience?

10x Genomics (NASDAQ:TXG) and Twist Bioscience (NASDAQ:TWST) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

In the previous week, Twist Bioscience had 9 more articles in the media than 10x Genomics. MarketBeat recorded 19 mentions for Twist Bioscience and 10 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 0.35 beat Twist Bioscience's score of 0.10 indicating that 10x Genomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	1 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Twist Bioscience	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

10x Genomics has a net margin of -12.18% compared to Twist Bioscience's net margin of -31.66%. 10x Genomics' return on equity of -9.33% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-12.18%	-9.33%	-7.30%
Twist Bioscience	-31.66%	-28.64%	-19.94%

10x Genomics has a beta of 1.99, suggesting that its share price is 99% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market.

84.7% of 10x Genomics shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by company insiders. Comparatively, 3.1% of Twist Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

10x Genomics has higher revenue and earnings than Twist Bioscience. 10x Genomics is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	19.81	-$43.54M	-$0.59	N/A
Twist Bioscience	$376.57M	34.14	-$77.67M	-$2.22	N/A

10x Genomics currently has a consensus target price of $53.93, indicating a potential downside of 44.82%. Twist Bioscience has a consensus target price of $115.27, indicating a potential downside of 43.77%. Given Twist Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Twist Bioscience is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.28
Twist Bioscience	2 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

10x Genomics beats Twist Bioscience on 9 of the 16 factors compared between the two stocks.

How does 10x Genomics compare to IQVIA?

IQVIA (NYSE:IQV) and 10x Genomics (NASDAQ:TXG) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

IQVIA has a net margin of 8.10% compared to 10x Genomics' net margin of -12.18%. IQVIA's return on equity of 30.25% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.10%	30.25%	6.54%
10x Genomics	-12.18%	-9.33%	-7.30%

89.6% of IQVIA shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 1.7% of IQVIA shares are held by company insiders. Comparatively, 8.8% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

IQVIA has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market. Comparatively, 10x Genomics has a beta of 1.99, suggesting that its stock price is 99% more volatile than the broader market.

IQVIA has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.31B	2.69	$1.36B	$8.06	33.07
10x Genomics	$642.82M	19.81	-$43.54M	-$0.59	N/A

IQVIA currently has a consensus price target of $264.31, indicating a potential downside of 0.84%. 10x Genomics has a consensus price target of $53.93, indicating a potential downside of 44.82%. Given IQVIA's stronger consensus rating and higher probable upside, research analysts clearly believe IQVIA is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
10x Genomics	1 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.28

In the previous week, IQVIA had 3 more articles in the media than 10x Genomics. MarketBeat recorded 13 mentions for IQVIA and 10 mentions for 10x Genomics. IQVIA's average media sentiment score of 0.51 beat 10x Genomics' score of 0.35 indicating that IQVIA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	3 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
10x Genomics	1 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

IQVIA beats 10x Genomics on 14 of the 17 factors compared between the two stocks.

How does 10x Genomics compare to Waters?

10x Genomics (NASDAQ:TXG) and Waters (NYSE:WAT) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

Waters has a net margin of 3.58% compared to 10x Genomics' net margin of -12.18%. Waters' return on equity of 11.27% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-12.18%	-9.33%	-7.30%
Waters	3.58%	11.27%	6.73%

84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 94.0% of Waters shares are held by institutional investors. 8.8% of 10x Genomics shares are held by company insiders. Comparatively, 0.3% of Waters shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

10x Genomics has a beta of 1.99, indicating that its share price is 99% more volatile than the broader market. Comparatively, Waters has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

10x Genomics currently has a consensus price target of $53.93, indicating a potential downside of 44.82%. Waters has a consensus price target of $437.10, indicating a potential downside of 0.76%. Given Waters' stronger consensus rating and higher possible upside, analysts plainly believe Waters is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.28
Waters	0 Sell rating(s)	6 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	2.85

Waters has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	19.81	-$43.54M	-$0.59	N/A
Waters	$3.17B	13.67	$642.63M	$4.01	109.84

In the previous week, 10x Genomics and 10x Genomics both had 10 articles in the media. 10x Genomics' average media sentiment score of 0.35 beat Waters' score of 0.22 indicating that 10x Genomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	1 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Waters	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Waters beats 10x Genomics on 12 of the 16 factors compared between the two stocks.

How does 10x Genomics compare to Illumina?

10x Genomics (NASDAQ:TXG) and Illumina (NASDAQ:ILMN) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 89.4% of Illumina shares are held by institutional investors. 8.8% of 10x Genomics shares are held by company insiders. Comparatively, 2.9% of Illumina shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Illumina had 10 more articles in the media than 10x Genomics. MarketBeat recorded 20 mentions for Illumina and 10 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 0.35 beat Illumina's score of 0.29 indicating that 10x Genomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	1 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Illumina	7 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

10x Genomics presently has a consensus target price of $53.93, indicating a potential downside of 44.82%. Illumina has a consensus target price of $219.69, indicating a potential downside of 25.20%. Given Illumina's stronger consensus rating and higher possible upside, analysts clearly believe Illumina is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.28
Illumina	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.44

Illumina has a net margin of 18.36% compared to 10x Genomics' net margin of -12.18%. Illumina's return on equity of 29.84% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-12.18%	-9.33%	-7.30%
Illumina	18.36%	29.84%	12.17%

Illumina has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	19.81	-$43.54M	-$0.59	N/A
Illumina	$4.34B	10.21	$850M	$5.36	54.79

10x Genomics has a beta of 1.99, indicating that its stock price is 99% more volatile than the broader market. Comparatively, Illumina has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

Summary

Illumina beats 10x Genomics on 12 of the 16 factors compared between the two stocks.

Get 10x Genomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TXG vs. The Competition

Export

Metric	10x Genomics	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.73B	$11.02B	$7.19B	$13.39B
Dividend Yield	N/A	1.44%	2.53%	18.16%
P/E Ratio	-136.71	31.75	273.36	26.34
Price / Sales	16.35	107.88	585.54	95.03
Price / Cash	N/A	27.95	79.41	53.24
Price / Book	12.93	6.87	11.04	6.33
Net Income	-$43.54M	$57.48B	$3.49B	$381.26M
7 Day Performance	-10.42%	-0.29%	-2.30%	-0.61%
1 Month Performance	28.75%	7.02%	-7.05%	-4.84%
1 Year Performance	538.13%	29.36%	5.64%	1.12%

10x Genomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TXG 10x Genomics	1.4797 of 5 stars	$80.66 -17.5%	$53.93 -33.1%	+666.6%	$12.73B	$642.82M	N/A	1,178	Gap Up High Trading Volume
PACB Pacific Biosciences of California	0.8713 of 5 stars	$1.71 +5.6%	$1.71 +0.1%	+92.6%	$503.55M	$160.01M	N/A	485	News Coverage Gap Up High Trading Volume
TWST Twist Bioscience	1.3597 of 5 stars	$179.60 -1.8%	$103.00 -42.7%	+559.8%	$11.46B	$376.57M	N/A	979	Trending News Insider Trade Gap Up
IQV IQVIA	3.0514 of 5 stars	$271.02 +0.2%	$253.25 -6.6%	+28.9%	$44.50B	$16.31B	33.62	93,000
WAT Waters	2.3003 of 5 stars	$443.80 +2.4%	$434.60 -2.1%	+33.9%	$42.59B	$3.17B	110.67	7,900

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TXG) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

10x Genomics (TXG) Competitors

TXG vs. PACB, TWST, IQV, WAT, and ILMN

How does 10x Genomics compare to Pacific Biosciences of California?

Summary

How does 10x Genomics compare to Twist Bioscience?

Summary

How does 10x Genomics compare to IQVIA?

Summary

How does 10x Genomics compare to Waters?

Summary

How does 10x Genomics compare to Illumina?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXG vs. The Competition

10x Genomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

10x Genomics (TXG) Competitors

TXG vs. PACB, TWST, IQV, WAT, and ILMN

How does 10x Genomics compare to Pacific Biosciences of California?

Do analysts prefer TXG or PACB?

Do institutionals and insiders believe in TXG or PACB?

Is TXG or PACB more profitable?

Does the media prefer TXG or PACB?

Which has more risk and volatility, TXG or PACB?

Which has stronger earnings and valuation, TXG or PACB?

Summary

How does 10x Genomics compare to Twist Bioscience?

Does the media prefer TXG or TWST?

Is TXG or TWST more profitable?

Which has more risk and volatility, TXG or TWST?

Do institutionals and insiders believe in TXG or TWST?

Which has stronger earnings and valuation, TXG or TWST?

Do analysts prefer TXG or TWST?

Summary

How does 10x Genomics compare to IQVIA?

Is IQV or TXG more profitable?

Do insiders and institutionals believe in IQV or TXG?

Which has more risk & volatility, IQV or TXG?

Which has stronger earnings & valuation, IQV or TXG?

Do analysts recommend IQV or TXG?

Does the media favor IQV or TXG?

Summary

How does 10x Genomics compare to Waters?

Is TXG or WAT more profitable?

Do institutionals & insiders believe in TXG or WAT?

Which has more risk and volatility, TXG or WAT?

Do analysts recommend TXG or WAT?

Which has stronger valuation & earnings, TXG or WAT?

Does the media prefer TXG or WAT?

Summary

How does 10x Genomics compare to Illumina?

Do institutionals and insiders believe in TXG or ILMN?

Does the media prefer TXG or ILMN?

Do analysts prefer TXG or ILMN?

Is TXG or ILMN more profitable?

Which has better earnings and valuation, TXG or ILMN?

Which has more volatility and risk, TXG or ILMN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXG vs. The Competition

10x Genomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools